Logo.png
Bacterial Vaginosis Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
15. Juli 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, July 15, 2024 (GLOBE NEWSWIRE) -- Bacterial Vaginosis Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight  The current therapeutic landscape of...
Transparency Market Research
Vaginitis Diagnostics Market to reach USD 4.1 billion in 2031, expanding at a CAGR of 9.5%: TMR Report
08. August 2023 08:15 ET | Transparency Market Research
Wilmington, Delaware, United States, Aug. 08, 2023 (GLOBE NEWSWIRE) -- The global vaginitis diagnostics market is projected to flourish at a CAGR of 9.5% from 2022 to 2031. As per the report...
HarrowHealth Logo.jpg
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
23. Oktober 2019 07:30 ET | Harrow Health, Inc.
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the...
HarrowHealth Logo.jpg
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
08. Oktober 2019 07:35 ET | Harrow Health, Inc.
BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa...
HarrowHealth Logo.jpg
Harrow Health Announces Launch of Mayfield Pharmaceuticals
31. Juli 2019 07:30 ET | Harrow Health, Inc.
NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate...
Melinta Therapeutics
Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
18. Januar 2018 07:00 ET | Melinta Therapeutics
NEW HAVEN, Conn., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...